Condition: Atopic Dermatitis · Sponsor: Galderma R&D
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
This description comes directly from the study's public registry record.
Galderma Research and Development · 817-961-5000 · clinical.studies@galderma.com
Always discuss trial participation with your own doctor first.
| Galderma Investigational Site - 8893 | Birmingham, Alabama, United States | Active Not Recruiting |
| Galdrma Investigational Site - 7077 | Phoenix, Arizona, United States | Recruiting |
| Galderma Investigational Site 7060 | Phoenix, Arizona, United States | Recruiting |
| Galderma Investigational Site - 8535 | Phoenix, Arizona, United States | Recruiting |
| Galderma Investigational Site - 7067 | Tucson, Arizona, United States | Not Yet Recruiting |
| Galderma Investigational Site - 7074 | Corona, California, United States | Not Yet Recruiting |
| Galderma Investigational Site 8636 | Fountain Valley, California, United States | Not Yet Recruiting |
| Galderma Investigational Site 8224 | Fremont, California, United States | Recruiting |
| Galderma Investigational Site 7099 | Los Angeles, California, United States | Not Yet Recruiting |
| Galderma Investigational Site 8553 | Newport Beach, California, United States | Recruiting |
| Galderma Investigational Site 7064 | Santa Monica, California, United States | Not Yet Recruiting |
| Galderma Investigational Site 7107 | Thousand Oaks, California, United States | Not Yet Recruiting |
+ 96 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06988605